Intermittent two-drug antiretroviral therapies maintain long-term viral suppression in real life in highly experienced HIV-infected patients.
Romain PalichBasma AbdiMarc WirdenGiota LouridaRoland TubianaAntoine FaycalMarc-Antoine ValantinLuminita SchneiderSophie SeangRachid AgherAnne SimonCathia SoulieMinh Patrick LêGilles PeytavinVincent CalvezAnne-Geneviève MarcelinChristine KatlamaPublished in: The Journal of antimicrobial chemotherapy (2021)
This observational study shows the potential for intermittent 2-DRs to maintain a high virological success rate, which should be assessed in larger prospective randomized studies.
Keyphrases
- hiv infected patients
- antiretroviral therapy
- high intensity
- hiv infected
- double blind
- open label
- sars cov
- placebo controlled
- human immunodeficiency virus
- phase iii
- hiv positive
- hiv aids
- human health
- randomized controlled trial
- clinical trial
- hepatitis c virus
- climate change
- risk assessment
- men who have sex with men
- study protocol